Assess whether RWE can replace or only supplement an RCT (aa9496)

Situation

Disproportionate reporting signal workbook arrived with an AdCom briefing document that overstates subgroup findings for clinical-development physician. That is a Pharma & Life Sciences Pharmacovigilance decision on RWE can replace or in a 505(b)(2) program relying on literature plus a bridging study.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• An AdCom briefing document that overstates subgroup findings is noise around an already-controlled Pharmacovigilance process in a 505(b)(2) program relying on literature plus a bridging study, given disproportionate reporting signal workbook.
• An AdCom briefing document that overstates subgroup findings is the event in disproportionate reporting signal workbook that forces RWE can replace for clinical-development physician under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a Pharmacovigilance program failure.
• Disproportionate reporting signal workbook cannot decide RWE can replace or yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move RWE can replace or for clinical-development physician.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). The follow-on Pharmacovigilance action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.